Ivosidenib: Targeted Therapy for Acute Myeloid Leukemia (AML) with IDH1 Mutation | |
Ivosidenib is a groundbreaking targeted therapy for patients with Acute Myeloid Leukemia (AML) who have an IDH1 mutation. By specifically inhibiting the IDH1 enzyme, Ivosidenib works to halt the abnormal cell growth driven by this mutation, offering a more personalized treatment approach. This innovative drug has shown promise in improving remission rates and extending survival, giving new hope to those with this aggressive form of leukemia. Discover how Ivosidenib is changing AML treatment for IDH1-mutated patients and advancing the fight against leukemia. Visit Now: https://luciuspharma.com/medicine/53307496022533 Email: info@lucius.la Call: +856 2052137046 Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos | |
Related Link: Click here to visit item owner's website (0 hit) | |
Target State: Vermont Target City : Xaythany Last Update : Nov 05, 2024 5:43 AM Number of Views: 38 | Item Owner : Vientiane Contact Email: Contact Phone: 2052137046 |
Friendly reminder: Click here to read some tips. |